Search PubMedSearch

Biomedical subjects

A G Wade

Publications and source records attributed to A G Wade.

12 recordsLinked to original sources

Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice.

In a double blind, randomized, parallel group study, 197 patients with osteoarthritis (OA) received nabumetone (1000 mg/day) or indomethacin (75 mg/day) for 6 weeks and doses could be doubled. Doubling the dose resulted in a 100 or 67% increase in pain relief with nabumetone or indomethacin, respectively. Significantly more patients experienced at least 1 severe adverse event with indomethacin than with nabumetone. With nabumetone, the incidence of adverse events did not increase with dose. However, with the increase in dose, the incidence of all adverse events and gastrointestinal events increased in indomethacin treated patients. Nabumetone was as effective as indomethacin for the treatment of OA. However, significantly fewer nabumetone treated patients experienced severe adverse events and the frequency of events did not increase with dose.

Adult

Long term management of duodenal ulcer in general practice: how best to use cimetidine?

Two hundred and sixty seven patients with duodenal ulceration were entered into a five year study of two strategies of treatment with cimetidine. Two thirds were treated continuously with 400 mg at bedtime supplemented by temporary increases in dosage if they had symptomatic relapses (group 1), and the remaining third were given intermittent "healing" doses for four to eight weeks if a symptomatic recurrence was judged to have occurred (group 2). Life table analysis showed that the probability of remaining free of clinically important symptoms five years after the start of treatment was 24% (95% confidence interval (CI) 15.5% to 32.6%) in group 1 compared with nil in group 2 (p less than 0.0001). The median values for the longest periods free from relapse for each patient were 108 weeks in group 1 and 32 weeks in group 2, respectively (p less than 0.0001; 95% CI of the median difference 36 to 76). Over the five years 10 patients suffered major complications, two requiring emergency surgery, while a further nine had elective surgery because of the failure of medical treatment. There were no deaths that could be attributed either to ulceration or to treatment with cimetidine. Medical management was therefore very satisfactory for most patients, though those treated continuously with cimetidine suffered considerably less from their ulcer symptoms. As 80% of patients studied relapsed during the two years after a healing course of cimetidine, continuous treatment will benefit many patients treated in general practice.

Actuarial Analysis

A double-blind comparison of meptazinol versus paracetamol and placebo in acute and chronic painful conditions presented to the general practitioner.

A double-blind study was carried out in 90 patients with acute or chronic painful musculoskeletal conditions of at least moderate severity to compare the effectiveness over a 72-hour period of oral treatment, 3 to 6 hourly, with 200 mg meptazinol, 1 g paracetamol and placebo. Assessments of pain by physicians and patients indicated that both active treatments produced effective analgesia compared with placebo. No significant differences were observed between meptazinol and paracetamol. The frequency of adverse effects reported was low and similar in all three treatment groups.

Acetaminophen

First impressions of the use of meptazinol in general practice.

Meptazinol which is a potent opiate antagonist analgesic has been assessed by the oral route at a dose of 200 mg 3-6 hourly. The analgesic profile shows a significant fall in pain score by 2 hours which was the earliest recording time. Satisfactory pain relief was maintained during 3 days of treatment. The side-effect profile was of a low order and there was no adverse effect on haematological and biochemical screens.

Adolescent

A patient compliance comparative study of three diuretics in the treatment of oedema.

Diurexan (xipamide) 40 mg daily was substituted for Navidrex-K (cyclopenthiazide 0.25 mg plus potassium 600 mg) or Moduretic (amiloride hydrochloride 5 mg plus hydrochlorthiazide 50 mg) in nineteen patients with oedema of cardiac origin. Comparative efficacy and patient acceptability were examined over a 4-week treatment period. In six patients their oedema was resolved and in a further seven their oedema was markedly reduced (six patients had no overt oedema pre-trial). The body-weight of nine patients decreased by an average of 1.4 kg whilst in seven patients it remained static and in three patients it increased by an average of 1.8 kg. Thirteen of the patients preferred Diurexan at the end of the 4-week trial period, four patients had no preference and two patients preferred their previous treatment.

Adult